arrow_back Trending Legislation
Share share

Drug Approval Changes: New Rules for Innovative Substances

This law changes how new drugs and biological products are defined and approved, focusing on the "active moiety" instead of the "active ingredient." This aims to standardize the approval process and may affect the availability of new therapies, potentially speeding up or slowing down the market introduction of certain drugs.
Key points
The definition of a "new chemical entity" in drug law has shifted from "active ingredient" to "active moiety," which may impact which drugs are considered innovative.
New rules for consulting advisory committees before approving certain drugs and biological products have been introduced, aiming to provide additional safety and efficacy evaluations.
The changes also affect drugs for rare pediatric diseases, which could influence their development and availability for patients.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Became Law
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity.
Print number: S 415
Sponsor: Sen. Cassidy, Bill [R-LA]
Process start date: 2021-02-24
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Drug Approval Changes: New Rules for Innovative Substances

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 415.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-02-24.

What are the main provisions?

Key points include:

  • The definition of a "new chemical entity" in drug law has shifted from "active ingredient" to "active moiety," which may impact which drugs are considered innovative.
  • New rules for consulting advisory committees before approving certain drugs and biological products have been introduced, aiming to provide additional safety and efficacy evaluations.
  • The changes also affect drugs for rare pediatric diseases, which could influence their development and availability for patients.

What is the specific legal status?

The current status is Became Law.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Cassidy, Bill [R-LA].

What is the latest detailed status?

The latest detailed status is: Became Public Law No: 117-9.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

Analysis and Potential Impact of S 415

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health